The HRP patients count recently has increased more than 100%. Doctors as well as patients have rated imedic and its services about 95%
satisfaction and most patients would continue and recommend others to use imedic. The authority has indicated that the program will continue
for the next 2 years. With the success of the HRP program, imedic proven to be far more superior than all other telemedicine tools and the
adoption rate has increased significantly. The Group is in the process of establish its presence through a joint venture with local pharmacy
chain in Hong Kong to provide online consultation at the pharmacy stores specifically for the chronic disease patients. Sputnik V vaccine
project is currently under review since the market dynamic has changed significantly.

https://www.zaobao.com.sg/realtime/china/story20220308-1250247

它的顧客群，大多數都是醫院和專科醫生。它的顧客群不是街邊賣 Pisang Goreng，賬期通常不會是現金term，應該是60天賬期。下個月，Q4報告就要公佈了，如果它連續4個季度都有增長，就可以看的出來，應該它的顧客群已經比較穩定了。下個月再看看它的Revenue/Sales, Total Debtors Amount 和 Cash 現金流量吧!

坦白說科技股是很難用 Accounting 的知識來算。你看大多數科技股，它的NTA都很低，可是股價都很高很高。只要它們的研發的系統一成熟，顧客群越來越多，它們的成本就會越來越底。它們剛開始會比較辛苦，可是如果一成熟，就會有很大很大的改變。

最近疫情，很多都走向未來高科技發展。它在馬來西亞的市場是很小很小，多數都是在海外，那些國家邁向高科技發展的國家。

它的股價應該很難底過0.30了，你要了解公司在4月有EMPLOYEE SHARE OPTION SCHEME, 價錢是RM0.235.

所以Q3有一個 ESOS Expenses RM4.6M.

科技股如果它們研發的系統一成熟，未來的利潤是會很高，可是主要的成本是不會高。因為之前已經研發了，只是要有一點管理成本。

如果再未來的兩個季度都能有很高和穩定的Revenue/Sales。公司的成長就可以看的出來了。

應該看它最新的 Q1, Q2 和 Q3 季度報告。科技股是很難從以前的Profit & Loss Account 和 Balance Sheet 看出來。如果沒有錯，它下個季度 Q4 業績報告應該是賺很多錢。因為Q3的業績報告，裡面有一個 ESOS Expenses （ RM4.6M ).

它最新的Q1，Q2 和 Q3 的 Revenue / Sales 都有很好的增長。

投資掛牌公司，最重要公司要有好的未來發展，大老闆會考慮到小股東一路來的支持( 就是大老闆要有好品德 )。

Actually in 2021 Q3 have an ESOS Expenses around RM4,630,000.00。

Otherwise its the profit will be more higher.

中美又要開戰了，會談不成功，就有好戲連台了。

中美又要開戰了，會談不成功，就有好戲連台了。

GST 的美夢短期不會成真了。

（布城18日讯）财政部长东姑赛夫鲁认为，在国家经济刚要复苏阶段，不适宜推介任何新税制，或对税制作出任何改变。

Q2, Q3, Q4 2020的業績報告都有改善了。感覺公司也知道如何解決這場疫情危機了。

請注意，MyEG的5年税务奖掖，将于今年4月截至了。

根据截至3月10日的3个月交易量加权均价1.75令吉，除红股股价为每股88仙。

感覺已經有聞到馬國要大選了。 議席在第15屆大選的談判最近感覺很熱。

https://www.chinapress.com.my/?p=2429438
有人知道现在到什么情况了嘛?

（吉隆坡6日讯）大股东兼联合创办人拿督程铁建和相关人士已掌握达企业（TA，4898，主板金融股）94.42%股权，收购活动已在周五（5日）画上句点。

达企业周五发文告指出，截至当天闭市，程铁健已持有该公司约23亿5712万股，相等于94.42%股权，并宣布停止收购活动。

由于程铁建无意维持达企业上市地位，交易所将在本月15日起，暂停达企业股票交易活动，并根据上市条例将其除牌。

早在2008年，程铁建已献议，以每股66仙的价格全购达企业，不过当时以失败告终。

去年12月，程铁建再次提出全购献议，出价每股65.5仙认购余下股权。

可以跨州，大选就应该不远了。

（吉隆坡6日讯）3年前，一场改朝换代，被认为是政治关联股的MyEG（MYEG，0138，主板科技股）遭遇连日大跌，市值在短短4个交易日遭砍接近三分之二。

一年前，冠病疫情肆虐，在这场危机中，MyEG果断进军医疗服务相关领域；随着业绩屡创新高，股价也逐步收复失地，站回2018年5月14日（大选之后首个交易日）之后的高峰。

3年来，MyEG是如何一步一脚印地，洗脱“国阵关联股项”的名称，并透过积极扩张与发展，重新赢回投资者的青睐？

集团创办人兼董事经理黄天顺，在接受《南洋商报》独家专访中，娓娓道出这段历程。

“我们一直致力和当今政府紧密合作，提出可以帮助政府实现目标的解决方案”，黄天顺如此解释该集团与政府的关系，无论是当朝，还是前朝。

MyEG的业绩也已经充分说明了此说法，尽管在改朝换代之后，股价遭到抛售而大幅走低，但该集团的业绩并未因此出现大幅波动。

在截于2018年6月杪的财年，MyEG全年净利为1.70亿令吉；而2020财年首三季，该集团的净利就已经达到1.93亿令吉。

业绩稳健上扬

由于间中两次更换财年截止日期，上述财年数据无法按年比较，但若以季度业绩来看，MyEG无论是营业额还是核心净利，过去3年来都保持着稳定上行的趋势。

而“提出可以帮助政府实现目标的解决方案”，更体现在过去一年，MyEG大肆进军冠病相关的医疗服务领域上。

对于一家电子政府服务供应商来说，踏足这个领域，看起来更像是“不务正业”。

不过，黄天顺解释道：“冠病的爆发迫使政府需要迅速反应；而作为我国领先的电子服务供应商，MyEG加紧提供我们的创新和解决方案，以帮助对抗病毒。”

本着这样的理念，过去一年来，MyEG在我国推出了为雇主提供冠病检测一站式门户网站；在印尼推出冠病追踪应用程式；在菲律宾开发冠病测试应用程式等。

该集团甚至与中国安徽智飞龙科马生物制药有限公司合作，在我国进行疫苗第三阶段临床试验，以及成为该疫苗我国的独家分销商。

（吉隆坡6日讯）3年前，一场改朝换代，被认为是政治关联股的MyEG（MYEG，0138，主板科技股）遭遇连日大跌，市值在短短4个交易日遭砍接近三分之二。

一年前，冠病疫情肆虐，在这场危机中，MyEG果断进军医疗服务相关领域；随着业绩屡创新高，股价也逐步收复失地，站回2018年5月14日（大选之后首个交易日）之后的高峰。

3年来，MyEG是如何一步一脚印地，洗脱“国阵关联股项”的名称，并透过积极扩张与发展，重新赢回投资者的青睐？

集团创办人兼董事经理黄天顺，在接受《南洋商报》独家专访中，娓娓道出这段历程。

“我们一直致力和当今政府紧密合作，提出可以帮助政府实现目标的解决方案”，黄天顺如此解释该集团与政府的关系，无论是当朝，还是前朝。

MyEG的业绩也已经充分说明了此说法，尽管在改朝换代之后，股价遭到抛售而大幅走低，但该集团的业绩并未因此出现大幅波动。

在截于2018年6月杪的财年，MyEG全年净利为1.70亿令吉；而2020财年首三季，该集团的净利就已经达到1.93亿令吉。

业绩稳健上扬

由于间中两次更换财年截止日期，上述财年数据无法按年比较，但若以季度业绩来看，MyEG无论是营业额还是核心净利，过去3年来都保持着稳定上行的趋势。

而“提出可以帮助政府实现目标的解决方案”，更体现在过去一年，MyEG大肆进军冠病相关的医疗服务领域上。

对于一家电子政府服务供应商来说，踏足这个领域，看起来更像是“不务正业”。

不过，黄天顺解释道：“冠病的爆发迫使政府需要迅速反应；而作为我国领先的电子服务供应商，MyEG加紧提供我们的创新和解决方案，以帮助对抗病毒。”

本着这样的理念，过去一年来，MyEG在我国推出了为雇主提供冠病检测一站式门户网站；在印尼推出冠病追踪应用程式；在菲律宾开发冠病测试应用程式等。

该集团甚至与中国安徽智飞龙科马生物制药有限公司合作，在我国进行疫苗第三阶段临床试验，以及成为该疫苗我国的独家分销商。

https://www.klsescreener.com/v2/news/view/799057

Following the Movement Control Order 2.0 as implemented by the Government of Malaysia to contain the spread of the COVID-19 outbreak, Bursa Malaysia Berhad (“Bursa Malaysia”) had vide its letter dated 17 February 2021 granted an extension of one (1) month’s time for listed issuers to submit their quarterly reports and annual reports which are due by 28 February 2021, 31 March 2021 and 30 April 2021.



The Board of Directors of the Company wishes to inform that the Company will utilise the extension of time granted by Bursa Malaysia and that the Unaudited Fourth Quarterly Report is targeted to be released on 3 March 2021.



This announcement is dated 26 February 2021.

QR on 26/2/2021

（吉隆坡18日讯）卫生部长拿督斯里阿汉峇峇宣布，国内数家政府医院将开始采用深喉唾液样本，进行新冠肺炎检测。

他指出，采取深喉唾液样本相比鼻咽和口咽拭子采样，方法更安全和无创，且可加快检测过程。

“民众也可自行收集深喉唾液，以节省个人防护装备。”

阿汉峇峇今日发文告指出，医药研究中心已对深喉唾液检测进行评估，证实适用于“逆转录聚合酶链式反应”（RT-PCR），至于深喉唾液用于快速抗原检测试则在研究中。

他指出，多个国家和地区已使用唾液进行检测，价格便宜，也是最一致的样本采集方法之一。



https://www.klsescreener.com/v2/news/view/791869

這個月尾，將公佈公司2020年的第四季財務報表，净利應該會高過RM8000万。

IRIS Corp Bhd has snagged the much sought after contract for the RM1.16 billion National Integrated Immigration System (NIIS).

The contract, which has a tenure of 4½ years or 54 months, is likely to be a game changer for the company.

In a brief conversation with The Edge, CEO Shaiful Subhan clarified earlier speculation that the contract would be awarded to a consortium.

“It (the award) is just to us, Iris, but of course, we will have subcontractors and we are open to partnerships,” he says.

Shaiful was tight-lipped on the contract’s impact on Iris’ bottom line, saying only that, “It’s decent, we are still working on it”. Market talk, however, has it that the contract will mean margins of at least double digits for the company.

When asked about the possibility of Iris undertaking the maintenance of the NIIS as well, which could nudge up the overall value of the award, Shaiful says, “It’s too early to talk about it; we just got the contract. It (maintenance) is dependent on deliverables. We have to deliver on the contract.”

However, considering that the contract entails testing, designing, developing, supplying, delivery, assembly, integration, data migration and integrating the entire system, it is likely that Iris will end up doing the maintenance of the NIIS as well. Margins for maintenance contracts can go as high as 15% of the contract value a year, but without more details, it is difficult to pinpoint the quantum.

In addition, variation orders could increase the contract value, but this is conjecture at press time.

When asked if Iris would seek out similar contracts in some of the other countries the company is operating in, Shaiful’s reply is “of course”. Iris has implemented immigration, identification and passport systems in 34 countries across the globe. It was the pioneer in its field, having come up with the ePassport in 1998.

Shaiful says Iris is in talks with the Malaysian government over other contracts but declines to comment further as the talks are confidential.

The award of NIIS to Iris quashes initial speculation that the contract would be shared among several companies in a consortium.

Towards the end of last year, market talk had it that the NIIS pie would be split between Iris and MyEg Services Bhd, and possibly even politically well-connected S5 Systems Sdn Bhd, a unit of S5 Holdings Inc, which is undertaking a reverse takeover of Ancom Logistics Bhd.

Other than MyEG, some of the other companies Iris pipped include Scicom (MSC) Bhd and Dagang Nexchange Bhd. HeiTech Padu Bhd, developer of the incumbent Malaysian Immigration System or myIMMS — first used in 1993 — was another bidder.

Interestingly enough, MyEG has acquired a 10% stake in S5 Holdings.

The NIIS contract was scheduled to be awarded last August but was delayed several times. Under the former Barisan Nasional government, Sistem Kawalan Imigresen Nasional or SKIN, the forerunner of NIIS, was undertaken and it was valued at RM3.5 billion. SKIN was proposed by Prestariang Bhd, now known as Awanbiru Technology Bhd.

However, the Pakatan Harapan government scrapped the SKIN project in December 2019, and sought an open tender to award the NIIS contract, to cut costs. At RM1.3 billion, NIIS is more than 60% cheaper than SKIN.

SKIN was slated to replace MyIMMs, which has received flak for some time. The Auditor General’s report in 2015 said the system was “not up to mark”. In 2018, it noted there were no records of 214,398 foreigners exiting Malaysia since mid-April that year. Also, MyIMMs experienced 4,489 breakdowns from 2016 to 2018.

Meanwhile, the NIIS is likely to be a boon for Iris.

For the six months ended September last year, Iris suffered a net loss of RM5.21 million from RM46.36 million in revenue. For the corresponding period a year ago, the company chalked up a net profit of RM19.4 million from 144.71 million in revenue.

Iris attributed the dip in revenue and losses for the first six months of 2020 to lower deliveries of e-passports and cards in the current year compared to 2019.

As at end-September last year, Iris had cash and bank balances of RM71.27 million, with RM25 million in both short-and long-term borrowings. Accumulated losses amounted to RM291.28 million.

Nevertheless, things have been picking up for the company.

Last September, it secured a US$27.54 million (RM110.8 million) contract in India for 15 million e-passports. In November 2019, the company forged a partnership with Metropolitan Office Pte Ltd in Sri Lanka to collaborate and explore business opportunities in e-passport, automated border control and attendance management solutions in the country.

Iris is led by president and managing director Datuk Paul Poh Yang Hong and Shaiful, who have been at the helm of the company since July and October 2017 respectively.

Yang Hong’s father Dr Poh Soon Sim is a substantial shareholder of Iris with 12.65% equity interest. Other substantial shareholders include Datuk Seri Robin Tan Yeong Chi

IRIS Corp Bhd has snagged the much sought after contract for the RM1.16 billion National Integrated Immigration System (NIIS).

The contract, which has a tenure of 4½ years or 54 months, is likely to be a game changer for the company.

In a brief conversation with The Edge, CEO Shaiful Subhan clarified earlier speculation that the contract would be awarded to a consortium.

“It (the award) is just to us, Iris, but of course, we will have subcontractors and we are open to partnerships,” he says.

Shaiful was tight-lipped on the contract’s impact on Iris’ bottom line, saying only that, “It’s decent, we are still working on it”. Market talk, however, has it that the contract will mean margins of at least double digits for the company.

When asked about the possibility of Iris undertaking the maintenance of the NIIS as well, which could nudge up the overall value of the award, Shaiful says, “It’s too early to talk about it; we just got the contract. It (maintenance) is dependent on deliverables. We have to deliver on the contract.”

However, considering that the contract entails testing, designing, developing, supplying, delivery, assembly, integration, data migration and integrating the entire system, it is likely that Iris will end up doing the maintenance of the NIIS as well. Margins for maintenance contracts can go as high as 15% of the contract value a year, but without more details, it is difficult to pinpoint the quantum.

In addition, variation orders could increase the contract value, but this is conjecture at press time.

When asked if Iris would seek out similar contracts in some of the other countries the company is operating in, Shaiful’s reply is “of course”. Iris has implemented immigration, identification and passport systems in 34 countries across the globe. It was the pioneer in its field, having come up with the ePassport in 1998.

Shaiful says Iris is in talks with the Malaysian government over other contracts but declines to comment further as the talks are confidential.

The award of NIIS to Iris quashes initial speculation that the contract would be shared among several companies in a consortium.

Towards the end of last year, market talk had it that the NIIS pie would be split between Iris and MyEg Services Bhd, and possibly even politically well-connected S5 Systems Sdn Bhd, a unit of S5 Holdings Inc, which is undertaking a reverse takeover of Ancom Logistics Bhd.

Other than MyEG, some of the other companies Iris pipped include Scicom (MSC) Bhd and Dagang Nexchange Bhd. HeiTech Padu Bhd, developer of the incumbent Malaysian Immigration System or myIMMS — first used in 1993 — was another bidder.

Interestingly enough, MyEG has acquired a 10% stake in S5 Holdings.

The NIIS contract was scheduled to be awarded last August but was delayed several times. Under the former Barisan Nasional government, Sistem Kawalan Imigresen Nasional or SKIN, the forerunner of NIIS, was undertaken and it was valued at RM3.5 billion. SKIN was proposed by Prestariang Bhd, now known as Awanbiru Technology Bhd.

However, the Pakatan Harapan government scrapped the SKIN project in December 2019, and sought an open tender to award the NIIS contract, to cut costs. At RM1.3 billion, NIIS is more than 60% cheaper than SKIN.

SKIN was slated to replace MyIMMs, which has received flak for some time. The Auditor General’s report in 2015 said the system was “not up to mark”. In 2018, it noted there were no records of 214,398 foreigners exiting Malaysia since mid-April that year. Also, MyIMMs experienced 4,489 breakdowns from 2016 to 2018.

Meanwhile, the NIIS is likely to be a boon for Iris.

For the six months ended September last year, Iris suffered a net loss of RM5.21 million from RM46.36 million in revenue. For the corresponding period a year ago, the company chalked up a net profit of RM19.4 million from 144.71 million in revenue.

Iris attributed the dip in revenue and losses for the first six months of 2020 to lower deliveries of e-passports and cards in the current year compared to 2019.

As at end-September last year, Iris had cash and bank balances of RM71.27 million, with RM25 million in both short-and long-term borrowings. Accumulated losses amounted to RM291.28 million.

Nevertheless, things have been picking up for the company.

Last September, it secured a US$27.54 million (RM110.8 million) contract in India for 15 million e-passports. In November 2019, the company forged a partnership with Metropolitan Office Pte Ltd in Sri Lanka to collaborate and explore business opportunities in e-passport, automated border control and attendance management solutions in the country.

Iris is led by president and managing director Datuk Paul Poh Yang Hong and Shaiful, who have been at the helm of the company since July and October 2017 respectively.

Yang Hong’s father Dr Poh Soon Sim is a substantial shareholder of Iris with 12.65% equity interest. Other substantial shareholders include Datuk Seri Robin Tan Yeong Chi

KUALA LUMPUR: The Institute of Medical Research (IMR) is currently evaluating the use of 'deep throat saliva' as a specimen for detection of SARS-CoV-2, the virus that causes Covid-19.

Dr Ravindran Thayan, head of the Virology Unit in the Infectious Diseases Research Centre, said IMR has evaluated saliva (early morning saliva) and deep throat saliva as an alternative sample for Covid-19 testing using RT-PCR Platform.

He said results indicated that those samples were equally as good as nasopharyngeal swabs (NPS) for testing Covid-19.

"These are important findings to enable the use of deep throat saliva instead of NPS and OPS (oropharyngeal swab).

"There will be reduced use of PPE (Personal protective equipment) and subjects can self-collect deep throat saliva.

"Currently, IMR is evaluating the use of the RTK Antigen to test using deep throat saliva," he said during a Covid-19 Emergency period engagement session organised by the Health Ministry with the media today.

Health director-general Tan Sri Dr Noor Hisham Abdullah, meanwhile, said health personnel must be trained to take the samples.

"It is only a sample detecting method. The tests (for Covid-19) remains the same, which is RT-PCR (reverse transcription-polymerase chain reaction) or RTK-Ag (Antigen Rapid Test Kits)."

Meanwhile, Dr Hani Mat Hussin, the National Public Health Laboratory (MKAK) director, said the Health Ministry has conducted a total of 6,336,804 Covid-19 tests from Jan 1, 2020, to Feb 3, 2021.

"Of that, 4,477,839 were RT-PCR tests and the remaining 1,858,965 tests were RTK-Ag."

中午過後，再來一個好休息，不漲都難。

1) Q4 2020 的業績報告要出來了。
2) 這個月尾，全馬國的外勞一定要冠病測試。
3) 馬國政府隨時隨地會批准上門冠病測試的服務。
4) 用中國的疫苗接種。

KUALA LUMPUR (Feb 4): My EG Services Bhd (MyEG) announced today that it will introduce an at-home saliva-based Covid-19 testing service in the Philippines this month to help the country's fight against the ongoing Covid-19 pandemic.

In a bourse filing, the company called the Covid-19 test a safe, fast, convenient and non-invasive method that can greatly enhance accurate detection and subsequent early intervention.

"As the exclusive distributor of the kit, MyEG will be making the service — the first of its kind in the Philippines market — available through its joint venture I-Pay MYEG Philippines Inc, in collaboration with IP Biotech, Inc, a licensed importer of vaccines, and medical devices in the Philippines, and Family Vaccine and Specialty Clinics, Inc, one of the largest chains of vaccination clinics in the country that delivers quality healthcare services to Filipinos," said MyEG.

It said the diagnostic kit enables on-site collection of saliva samples at home or at workplace by licensed medical professionals. The samples will then be sent to partner laboratories for processing, with test results delivered within one to two working days.

According to MyEG, the saliva-based kit — which has received the approval of the Food and Drug Administration of the Philippines and has also been approved in Singapore and Indonesia — can also detect the new strains of Covid-19 (SARS-CoV-2) that have been reported in the United Kingdom, South Africa, and Brazil.

"Meanwhile, similar kits have also been granted emergency use authorisation from the Food and Drug Administration in the United States, where the likes of retail giant Costco are pioneering the use of such at-home, mail-in Covid-19 tests.

"MyEG is introducing this game-changing approach, which is more efficient and far less invasive than conventional methods without compromising on accuracy, to enable more people to be tested, thus providing a timely and much-needed boost in the fight against the spread of Covid-19 that has seen available healthcare resources worldwide being increasingly stretched to their limits," it added.

This new approach will not only make Covid-19 testing much more accessible, but will also ensure better protection for people and front line healthcare providers by reducing the need for close contacts since samples can be collected at home or workplace, the group noted.

Apart from the Philippines, MyEG also plans to deploy a similar approach to testing in Malaysia, pending approval from the relevant regulators for the use of the test kit.

"Making such a hassle-free approach to testing available to the Malaysian public would be very much in line with the convenient, doorstep delivery of a myriad government and ancillary services that MyEG is already known for. Furthermore, this effort can help ease the pressure on the country's front line workers who have been working tirelessly in the past year," it said.

In the wake of the outbreak of the Covid-19 virus, the group said it has leveraged its strengths and expertise as a leading digital services provider in the region to embark on a number of significant initiatives, guided by an overarching vision to provide a holistic solution to help in the fight against Covid-19.

"These initiatives include, among others, a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co, Ltd to conduct Phase 3 trials, obtain Halal certification and distribute Chinese company's vaccine in Malaysia, the provision of MySafeTravel, a digital health pass system to facilitate inbound travellers' adherence to mandatory Covid-19 testing and quarantine requirements as well as the provision of a one-stop portal for the screening of workers in the country," it added.

At the noon break, shares of MyEG were eight sen or 4.32% higher at RM1.93, with some 9.95 million shares done. This values the group at RM7.09 billion.

（八打灵再也4日讯）MYEG服务公司计划在大马推行“家庭式采集唾液样本”的冠病检测服务，目前等待有关监管机构批准，以被允许采用类似的冠病测试方式。

该公司今日发文告指出，这种采集唾液样本的冠病检测服务，是以安全及非侵入性检测的方式加速筛检工作，协助政府对抗疫情。

文告说，唾液试剂盒是由拥有执照的医疗专业人员在家里或是工作地点的现场收集唾液样本，接着将样本送到合作伙伴的实验室进行处理，并在1至2个工作日内提供测试结果。

文告说，MYEG服务公司将会于本月在菲律宾首次推出采集唾液样本的冠病检测服务。

“有关试剂盒已经得到菲律宾食品和药物管理局的批准，并在新加坡和印尼获得批准。在这之前，英国、南非及巴西也曾采用类似的测试方式，以检测冠病。”

文告表示，该试剂盒也获得美国食品和药物管理局（FDA）的紧急使用授权，如美国零售巨头Costco之类的公司亦率先使用这种采用唾液样本的冠病检测。

文告指出，作为该试剂盒的独家经销商，MYEG将通过其合资企业即I-Pay MYEG Philippines Inc.与IP Biotech Inc.公司合作提供该项服务，有关公司也是菲律宾疫苗和医疗设备的特许进口商。

文告说，至于作为菲律宾最大疫苗接种诊所链之一，家庭疫苗和专科诊所有限公司将会提供优质的医疗保健服务。

文告表示，MYEG服务公司所采用的新方式不但使到检测变得更加容易，而且通过减少密切接触的需要，确保人民和前线医护人员可以舒适地在家中采集样本进行冠病检测，也能获得足够的保护。

“这项方式的效率更高、侵入性更小，且不影响检测结果的准确度，从而让更多人能够接受冠病测试，在对抗疫情中也发挥了更大的作用，有助于遏制冠病的传播。”

（八打灵再也4日讯）MYEG服务公司计划在大马推行“家庭式采集唾液样本”的冠病检测服务，目前等待有关监管机构批准，以被允许采用类似的冠病测试方式。

该公司今日发文告指出，这种采集唾液样本的冠病检测服务，是以安全及非侵入性检测的方式加速筛检工作，协助政府对抗疫情。

文告说，唾液试剂盒是由拥有执照的医疗专业人员在家里或是工作地点的现场收集唾液样本，接着将样本送到合作伙伴的实验室进行处理，并在1至2个工作日内提供测试结果。

文告说，MYEG服务公司将会于本月在菲律宾首次推出采集唾液样本的冠病检测服务。

“有关试剂盒已经得到菲律宾食品和药物管理局的批准，并在新加坡和印尼获得批准。在这之前，英国、南非及巴西也曾采用类似的测试方式，以检测冠病。”

文告表示，该试剂盒也获得美国食品和药物管理局（FDA）的紧急使用授权，如美国零售巨头Costco之类的公司亦率先使用这种采用唾液样本的冠病检测。

文告指出，作为该试剂盒的独家经销商，MYEG将通过其合资企业即I-Pay MYEG Philippines Inc.与IP Biotech Inc.公司合作提供该项服务，有关公司也是菲律宾疫苗和医疗设备的特许进口商。

文告说，至于作为菲律宾最大疫苗接种诊所链之一，家庭疫苗和专科诊所有限公司将会提供优质的医疗保健服务。

文告表示，MYEG服务公司所采用的新方式不但使到检测变得更加容易，而且通过减少密切接触的需要，确保人民和前线医护人员可以舒适地在家中采集样本进行冠病检测，也能获得足够的保护。

“这项方式的效率更高、侵入性更小，且不影响检测结果的准确度，从而让更多人能够接受冠病测试，在对抗疫情中也发挥了更大的作用，有助于遏制冠病的传播。”

（八打灵再也4日讯）MYEG服务公司计划在大马推行“家庭式采集唾液样本”的冠病检测服务，目前等待有关监管机构批准，以被允许采用类似的冠病测试方式。

该公司今日发文告指出，这种采集唾液样本的冠病检测服务，是以安全及非侵入性检测的方式加速筛检工作，协助政府对抗疫情。

文告说，唾液试剂盒是由拥有执照的医疗专业人员在家里或是工作地点的现场收集唾液样本，接着将样本送到合作伙伴的实验室进行处理，并在1至2个工作日内提供测试结果。

文告说，MYEG服务公司将会于本月在菲律宾首次推出采集唾液样本的冠病检测服务。

“有关试剂盒已经得到菲律宾食品和药物管理局的批准，并在新加坡和印尼获得批准。在这之前，英国、南非及巴西也曾采用类似的测试方式，以检测冠病。”

文告表示，该试剂盒也获得美国食品和药物管理局（FDA）的紧急使用授权，如美国零售巨头Costco之类的公司亦率先使用这种采用唾液样本的冠病检测。

文告指出，作为该试剂盒的独家经销商，MYEG将通过其合资企业即I-Pay MYEG Philippines Inc.与IP Biotech Inc.公司合作提供该项服务，有关公司也是菲律宾疫苗和医疗设备的特许进口商。

文告说，至于作为菲律宾最大疫苗接种诊所链之一，家庭疫苗和专科诊所有限公司将会提供优质的医疗保健服务。

文告表示，MYEG服务公司所采用的新方式不但使到检测变得更加容易，而且通过减少密切接触的需要，确保人民和前线医护人员可以舒适地在家中采集样本进行冠病检测，也能获得足够的保护。

“这项方式的效率更高、侵入性更小，且不影响检测结果的准确度，从而让更多人能够接受冠病测试，在对抗疫情中也发挥了更大的作用，有助于遏制冠病的传播。”

（吉隆坡4日讯）MyEG服务（My E.G. Services Bhd）今日指出，将于本月在菲律宾推出一个居家唾液检测新冠肺炎病毒的服务，帮助该国对抗疫情。

该集团向大马交易所报备，该新冠检测是安全、快速、方便且无创的方法，可以大大提高准确的检测和随后的早期干预。

“作为该试剂盒的独家经销商，MyEG将通过与IP Biotech, Inc及Family Vaccine and Specialty Clinics, Inc组成的联营公司I-Pay MYEG Philippines Inc，在菲律宾市场提供首个此类服务。”

MyEG表示，这种诊断试剂盒可以由持牌医疗专业人员在家中或职场现场采集唾液样本。样本将送往合作实验室，并在一至两个工作日取得检测结果。

据该集团说，唾液试剂盒已获得菲律宾食品药品管理局，以及新加坡和印尼的批准，也可以检测在英国、南非和巴西出现的新冠新菌株。

同时，美国食品药品监督管理局（FDA）也批准了类似试剂盒的紧急使用授权，零售巨头好市多（Costco）等公司率先使用这种检测。

除了菲律宾，MyEG还计划在大马采用类似的检测方法，目前有待相关单位批准使用该试剂盒。

“为大马民众提供这种检测服务，将非常符合MyEG提供便捷、上门服务的宗旨。此外，这将有助于缓解前线人员的压力。”

截至3时23分，该股扬11仙或5.95%，报1.96令吉，共1887万8600股成交。



（编译：陈慧珊）

（吉隆坡4日讯）MyEG（MYEG，0138，主板科技股）宣布，将在本月为菲律宾推出一款上门冠病测试的服务，旨在帮助该国加速和强化测试过程以对抗疫情。

该公司今日发布文告指出，这项通过采取唾液进行测试服务，所使用的试剂是由MyEG独家分销，并由联营公司I-Pay MYEG菲律宾公司提供上门服务。

持照医护人员可在家中或工作现场，使用该试剂来收集人们唾液样本，并将样本送往合作的实验室进行检测，报告结果可在2个工作日内出炉。

MyEG、菲律宾IP生物科技公司，及家庭疫苗和专科诊所公司，一起合作联营I-Pay MYEG。

IP生物科技是家持照疫苗和医疗设备进口商，而家庭疫苗和专科诊所公司，则是当地最大疫苗接种连锁诊所之一。

（吉隆坡4日讯）MyEG（MYEG，0138，主板科技股）宣布，将在本月为菲律宾推出一款上门冠病测试的服务，旨在帮助该国加速和强化测试过程以对抗疫情。

该公司今日发布文告指出，这项通过采取唾液进行测试服务，所使用的试剂是由MyEG独家分销，并由联营公司I-Pay MYEG菲律宾公司提供上门服务。

持照医护人员可在家中或工作现场，使用该试剂来收集人们唾液样本，并将样本送往合作的实验室进行检测，报告结果可在2个工作日内出炉。

MyEG、菲律宾IP生物科技公司，及家庭疫苗和专科诊所公司，一起合作联营I-Pay MYEG。

IP生物科技是家持照疫苗和医疗设备进口商，而家庭疫苗和专科诊所公司，则是当地最大疫苗接种连锁诊所之一。

（吉隆坡4日讯）MyEG（MYEG，0138，主板科技股）宣布，将在本月为菲律宾推出一款上门冠病测试的服务，旨在帮助该国加速和强化测试过程以对抗疫情。

该公司今日发布文告指出，这项通过采取唾液进行测试服务，所使用的试剂是由MyEG独家分销，并由联营公司I-Pay MYEG菲律宾公司提供上门服务。

持照医护人员可在家中或工作现场，使用该试剂来收集人们唾液样本，并将样本送往合作的实验室进行检测，报告结果可在2个工作日内出炉。

MyEG、菲律宾IP生物科技公司，及家庭疫苗和专科诊所公司，一起合作联营I-Pay MYEG。

IP生物科技是家持照疫苗和医疗设备进口商，而家庭疫苗和专科诊所公司，则是当地最大疫苗接种连锁诊所之一。

The kit has received the approval of the Food and Drug Administration in the Philippines, as well as by authorities in Singapore and Indonesia.

該工具包已獲得菲律賓食品藥品監督管理局以及新加坡和印度尼西亞當局的批准。

接下來馬來西亞也一定會批准用。

Myeg 多走出外國市場比較好啦！


（吉隆坡29日讯）MyEG（MYEG，0138，主板科技股）参与北京中科深智科技有限公司，高达数千万人民币的A轮融资。

MyEG今日发表文告表示，其独资子公司MyEG资本私人有限公司，参与了这家主攻虚拟直播、实时动画的动画内容生产公司的融资活动。

其余参与融资的，还包括有金江沙创投（GSR Ventures），以及盛景嘉成（PeakView Capital）等。

在这之前，英诺天使基金成为了中科深智的天使投资人。

中科深智于2016年4月在北京成立，聚焦全栈式实时动画和虚拟直播技术，为客户实现虚实影像合成、虚拟数字人机交互服务；并于最近推出了全天候在线的AI虚拟直播带货新产品。

MyEG资本是MyEG旗下的风险投资臂膀，过去数年来积极投资于马中两地的初创企业。

今日闭市，MyEG报1.92令吉，平盘，成交量1128万730股。

（吉隆坡17日讯）卫生部临床试验研究所（ICR）表示，由中国医学科学院医学生物学研究所（IMBCAMS）研发的疫苗已获得清真认证。

有关疫苗取得了大马伊斯兰发展局（JAKIM）的清真认证批准及筛查后，将在我国进行第三阶段临床试验。

根据卫生部临床试验研究所发布的常见问题，在这个临床试验中，3000名健康志愿者将分别接种疫苗及注射安慰剂（placebo），但他们必须符合先决条件才能被接纳，其中包括18岁以上且从未感染冠病。

志愿者需符合从未感染冠病的原因是因为曾感染冠病者，可能对冠病病毒已有免疫力；因此进行临床试验前，会事先检查志愿者的健康状况。

有关试验可能显示接种疫苗及注射安慰剂有效性，以及来自各背景的人士之间的研究结果。

常见问题中提到，每名志愿者将免费接种两剂疫苗，第二次接种会在14天后。

此外，志愿者在表明同意接受及签署参与该试验的协议后，将被给予补偿及车马费，但不会获得报酬。

第三阶段的临床试验将涵盖至少12个月，涉及6次后续访问及24通电话。

佛教裡有一句話說 ：“ 心善一切善， 心惡一切惡。 ” 主耶穌說 ：“ 神愛世人 ”。有人說 ：“ 我愛吃人。 ” 哈哈！

相信很多TA & TAGB的小股東的老本，棺材本，醫藥費，孩子大學費都給一家人騙去了。

（吉隆坡14日）独立顾问DWA谘询有限公司表示，大股东程铁建和友好伙伴以每股65.5仙出价收购达企业（TA,4898,主板金融服务组）“不公平”却“合理”，建议小股东接受要约。

根据报告，尽管程铁建的出价高于达企业当时股价和12个月平均股价，但却低于合理估值。

DWA说，达企业的分类加总估值法（SOPV）计算出合理价介于2令吉25仙至2令吉26仙，而献购价却低了高达71.11至71.24%，因此这并不公平。

不过，DWA表示，达企业的股票流动率不高，因此要约截止后不易脱售，况且基于程铁建无意保留达企业的上市地位，若最终公众持股比重未能达标，该公司将被迫下市，股票也无法公开交易。

DWA补充，程铁建和友好伙伴的总持股已达77.75%，足够通过或阻断大会上的任何决议，包括普通决议（至少50%），及特别决议（至少75%）。

鉴于上述因素，DWA认为，献购要约是合理的。

（八打灵再也16日讯）卫生部临床试验研究所（ICR）今天在推特发出三语通告，寻找志愿者进行冠病疫苗临床试验，为寻找安全有效的疫苗尽一分力。

据有关通告指出，任何18岁以上的成年人都可以参与此次的临床试验，

不过，通告也提醒，进行疫苗临床试验的志愿者，除了可能可以对冠病免疫，同时获得冠病PCR检测之外，也可能会面对一些潜在风险。

“可能导致的风险有注射疫苗后的常见反应，例如注射处出现疼痛、红肿及瘙痒，以及疲惫、发热、腹泻等。”

昨天首相宣布，马國将从1月21日开始，针对中国研发的冠病疫苗，展开第三期临床试验。

（吉隆坡10日讯/独家报导）我国与中国医学科学院医学生物学研究所（IMBCAMS），合作展开的新冠肺炎疫苗第三阶段临床试验，已正式获得马来西亚药剂监管局（NPRA）批准，而我国卫生部预计在2周内收到这批来自中国的疫苗。

卫生总监丹斯里诺希山受询时，向《中国报》证实这上述消息。

“是的，所有申请都在1月7日受批，包括临床试验研究准证。

“大马药剂监管局已批准在9家政府医院，展开IMBCAMS疫苗的临床试验研究。一旦我们收到正式信函后，我们会准备一个汇报会，我将会作出宣布。”

“我们预计将在2周内收到（这批）来自中国的疫苗。”

据了解，这或许会是第一批抵达我国的新冠肺炎疫苗，唯这批疫苗现阶段只用于临床试验用途。

诺希山也补充，卫生部会持续原定的计划，即招募3000名志愿者者，参与此次的第三期临床试验。

他也提到，这类疫苗临床试验早前已在多国展开，比如印尼去年就对中国北京科兴生物制品公司（Sinovac）研发的疫苗，展开了临床试验。

据报导，诺希山是在去年11月尾披露，我国将与IMBCAMS合作展开疫苗临床试验，当时原本预计在12月尾展开。

据了解，吉打双溪大年苏丹阿都哈林中央医院，日前已在线上招募临床试验志愿者。

（吉隆坡10日讯/独家报导）我国与中国医学科学院医学生物学研究所（IMBCAMS），合作展开的新冠肺炎疫苗第三阶段临床试验，已正式获得马来西亚药剂监管局（NPRA）批准，而我国卫生部预计在2周内收到这批来自中国的疫苗。

卫生总监丹斯里诺希山受询时，向《中国报》证实这上述消息。

“是的，所有申请都在1月7日受批，包括临床试验研究准证。

“大马药剂监管局已批准在9家政府医院，展开IMBCAMS疫苗的临床试验研究。一旦我们收到正式信函后，我们会准备一个汇报会，我将会作出宣布。”

“我们预计将在2周内收到（这批）来自中国的疫苗。”

据了解，这或许会是第一批抵达我国的新冠肺炎疫苗，唯这批疫苗现阶段只用于临床试验用途。

诺希山也补充，卫生部会持续原定的计划，即招募3000名志愿者者，参与此次的第三期临床试验。

他也提到，这类疫苗临床试验早前已在多国展开，比如印尼去年就对中国北京科兴生物制品公司（Sinovac）研发的疫苗，展开了临床试验。

据报导，诺希山是在去年11月尾披露，我国将与IMBCAMS合作展开疫苗临床试验，当时原本预计在12月尾展开。

据了解，吉打双溪大年苏丹阿都哈林中央医院，日前已在线上招募临床试验志愿者。

（吉隆坡8日讯）MyEG（MYEG，0138，主板科技股）和中国安徽智飞龙科马生物制药，计划在我国进行的冠病疫苗第三期临床试验，已获得卫生部的肯定和支持。

该公司向交易所报备，是在今日收到卫生部与大马临床研究中心（CRM）的肯定，为将在我国开始进行的临床试验给予支持和帮助。

同时，MyEG和智飞龙科马需遵守有关这类临床试验的现有法律和条规。

“董事部致力于确保在不久将来，可开始这项临床试验。”

MyEG是在上月7日宣布合作消息，并协助中国伙伴冠病疫苗取得回教发展局（JAKIM）的清真认证，并成为我国独家分销商。

这将是在我国卫生部管辖之下，首个进行的最后阶段疫苗试验。

另外，智飞龙科马是挂牌于深圳交易所的重庆智飞生物制品股份有限公司的子公司，主要研发人体使用疫苗，且还是中国5家进入冠病疫苗第三阶段临床试验的其中一家。

闭市时，MyEG挂收1.75令吉，跌6仙或3.31%，成交量2886万5600股。

現在TAGB的股東還可以轉去TA，到15/3/2021前

随着私有化活动完成，达全球（TAGB,5158,主板产业组）将于下周二（12日）除牌。

此前，大股东达企业（TA,4898,主板金融服务组）以每股28仙现金，或是1股换0.4211股达企业新股比例展开私有化计划。

@hitgirl47, 他爸爸本身是有一點產業，不過都是TT的兄弟姐妹們都有份。照現在的情況看，TA是不可能有大股東會買入了，所以TT出收購價，也只是一個程序而已。他會不會收購高過75%，就看小股東們能撐多久，哈哈！相信很多以前投資的小股東都拿不回母錢。

哎呀！TT 只是在演戲啦！他只是拉長時間給小股東們吃不消，過後他慢慢買入。這次疫情，對公司的酒店和房產業也影響很大。今年肯定沒有什麼起色了。